Plain-English translation of NCT05827549 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether personalizing treatment plans based on specific features of a child's relapsed leukemia can lead to better outcomes. Depending on the risk level of the disease, participants will receive different combinations of chemotherapy drugs and sometimes a medication called blinatumomab, which helps the immune system fight leukemia cells. The goal is to find the most effective approach for each child's specific situation.
When leukemia comes back after initial treatment, it becomes much harder to treat. This medication and other drugs work in different ways to attack leukemia cells, but doctors don't yet know the best combination and order to use them for different types of relapsed disease. This trial aims to figure out which treatment plans work best based on how aggressive the disease is and other characteristics.
You likely qualify if…
You likely don't qualify if…
Based on how aggressive your disease is, you will receive a customized treatment plan that includes cycles of chemotherapy (called reinduction, consolidation, and intensification phases) and possibly the medication blinatumomab. Some participants will also need a stem cell transplant. Throughout the trial, you will have regular hospital visits for treatment infusions, blood tests, and imaging scans to monitor how well the treatment is working. The exact length and intensity of treatment depends on your disease risk group.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea